

BioPorto

Økonomisk Ugebrev October 8th, 2026

Klaus Juhl Wulff, CFO

Forward-looking Statements

References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matter contained herein. By viewing or receiving or reading this presentation or attending any meeting where this presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below.

This presentation contains forward-looking statements. Words such as “believe”, “expect”, “may”, “plan”, “strategy”, “estimate”, “target” and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation concerning our plans, objectives, goals, future events and performance are forward-looking statements. They involve risks, uncertainties and other factors, which may cause actual results, performance and achievements to differ materially from the results discussed in the forward-looking statements. These include numerous assumptions, risks and uncertainties, many of which are beyond BioPorto’s control. These risks and uncertainties are described from time to time in BioPorto’s Announcements and in its 2025 Annual Report under Risk Factors. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date of this presentation.

This presentation is for information purposes only and does not constitute an offer to sell or a solicitation of any offer to buy any securities issued by the Company in any jurisdiction. The information contained herein is not for distribution in the United States of America. This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The Company’s securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to offer or solicit an offer to buy any securities in the Company in the United States or to make a public offering of the securities in the United States. Company securities may be sold only to qualified institutional buyers (as defined in Rule 144A under the Securities Act) in reliance on Rule 144A.

© Copyright BioPorto

BioPorto; invest in Acute Kidney Injury (AKI)

Clear inflection points for an early-stage in vitro diagnostics (IVD) company



Clinical proven AKI solution …


… a focused company …



… clear future inflection points

The ”Forward” Strategic Plan

*Focus on execution of **Market Access** & **Commercialization** to transform kidney care*



ASPIRATIONS

2H 2028 Cash Flow Positive

FY 2028 Revenue 135-185m DKK

FY 2028 EBITDA% +15%

bioporto

The unmet AKI need

The clinician's, patient and society perspective

Need for earlier detection

1 in 5 hospitalized patients develop AKI, up to 2 in 3 ICU patients* and kidney injury often develops silently, with few or no symptoms during the early stages

Need for better outcomes

Up to 58% mortality*, 12% dialysis risk*, and prolonged hospitalization

Need for lower healthcare burden

AKI is associated with 3-6 additional hospital days*, greater ICU resource utilization, and substantial healthcare costs

AKI is common, missed early, and costly



$700m

addressable ICU market*


*Sources: Xu et al., Clin Kidney J. 2023; Melo et al., PLoS ONE 2020; Pickkers et al., Intensive Care Med. 2021. ICU AKI mortality reported across published cohorts (FINNAKI; Harris et al.). Critically ill adults requiring dialysis (Hoste et al.; Silver et al.). Zeng et al. Clin J Am Soc Nephrol. 2014; Silver et al. Nephron. 2017. Addressable market based on management assessment.

bioporto

The clinical challenge considering AKI


Kidney injury is common (20%), often silent, and currently typically detected too late*

Adequate Filtration & Undamaged or Reduced Filtration & Injured



Kidney Nephron

Current standard of care focus on the functional filtration



Functional detection takes time

* Susantitaphong P. CJASN. 2014;9(6), Kaddourah A. N Engl J Med. 2017, 3. Sutherland SM, CJASN. 2013;8(10), 4. Hoste EA. Intensive Care Med. 2015, 5. Silver SA. Nephron. 2017;137

BioPorto's technology & regulatory status

Pediatric FDA-cleared kidney injury biomarker positioned for broader market expansion

Technology




Adult Clinical Validation Study

designed to **identifying adult patients at risk** of developing moderate-to-severe AKI at ICU

FDA Adult Clearance **Mid 2028**

open an **addressable market >20x** the pediatric commercial market



© Copyright BioPorto |

bioporto

Business Update anno September 2026

Consistent progress in the 10 months from initiation of the Forward Strategy

Market Access

1. Adult Cut-off Study Completion Jan26
2. Pre-Sub & Meeting with FDA Mar/Jun26
3. Adult Validation Study Initiation Aug26

Commercialization

- 41% US RUO growth y-o-y 1H26
- +10 new US RUO hospitals in 1H26
- KDIGO draft Guideline Mar26

Scaling BioPorto


- Funding by AntiBody Spin-off Apr26
- Established R&D in DK Spring26
- Established Advisory Board* Jun26

*Members: (i) **Dana Fuhrmann**, Pediatric Intensivist and Nephrologist, Cincinnati Children's Hospital, Ohio, USA (ii) **Daniel Englemann**, Cardiac Surgeon, Baystate Medical Center, Massachusetts, USA, (iii) **Joe El Khoury**, Director Clinical Chemistry and Laboratory Medicine, Yale New Haven Health, Connecticut, USA, (iv) **Jun Oh**, Pediatric Nephrologist, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany, (v) **Salvatore Di Somma**, Cardiologist and Internist, Professor of Emergency Medicine La Sapienza of Rome, Rome, Italy

© Copyright BioPorto

+60 Hospitals by end of 2026 – Creating Adoption

Expected Development of # of US Hospitals from 2024-2026




- Creating **awareness** and **understanding**; to create the future demand
- NGAL **Research Use Only** (RUO) & continued focus on the Pediatric segment
- Focus on the market in North America; initiating multiple **new processes**
- Support the released product for the Roche instrument Cobas 501 **for Pediatric segment**

© Copyright BioPorto

NGAL Sales US continuing strong growth

US NGAL RUO sales (accumulated 12 months rolling at constant exchange rates)



Exchange rate at DKK 6.5 to USD 1

Key financials for H1 2026

Total NGAL operative* revenue of DKK 15.2 million, an increase of 34% compared to H1 2025 measured in constant currency (25% growth measured in DKK).

Total operative* ** revenue for H1 of DKK 19.1 million, an increase of 31% measured in constant currency compared to H1 2025 (22% growth measured in DKK).

Operative* adjusted EBITDA loss of DKK 31.4 million, which is a decrease of 33% compared to H1 2025.

Cash at hand end of H1 2026 of DKK 75.6 million, during Q2 DKK 54 million positive cash flow from divestment of AntiBody business

*Operative meaning excluding the effect of the voluntary product recall, which has no connection to the business activities in H1 2026
**Excluding AntiBody revenue due to divestment of AntiBody business in April 2026

© Copyright BioPorto

What has happened since H1 2026 until now?

BioPorto signed **agreement with ProPharma as the Clinical Research Organization in the ProNephro AKI ® U.S. Adult Urine NGAL Validation study**, following its involvement in the preceding AKI cut-off study

First **US clinical site activated** as a part of the ProNephro AKI ® U.S. Adult Urine NGAL Validation Study

First patient enrolled into the ProNephro AKI® U.S. Adult Urine NGAL Validation Study



Continue to deliver on our Forward Strategy and commercial progress. Q3 financials to be announced Nov 19th

© Copyright BioPorto

2026 Financial Guidance

Unchanged following the AntiBody divestment in April

Total revenue in 2026



DKK 38-48 million (48-58)*

Total NGAL revenue in 2026



DKK 33-42 million (33-42)*

Adjusted EBITDA loss in 2026



DKK 58-68 million (50-60)*

Expected NGAL revenue growth of 20-50% in 2026

Lower expected adjusted EBITDA loss in 2026 vs 2025

* Original guidance announced in Feb 2026 and confirmed in the 2025 Annual Report prior to divestment of AntiBody business

bioporto

Why BioPorto as the investment

An opportunity at the changing intersection of diagnostics & kidney care



Large Unmet Need



Proven Technology



Regulatory & KOL Foundation



Competitive Position

$700m-$3bn

Market Opportunity



Scalable Growth

Questions & Answers

IR Contact
Klaus Juhl Wulff, CFO – kjw@bioporto.com
+45 2563 3990 | bioporto.com

© Copyright BioPorto |